Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iclaprim - Motif Bio

Next Previous
X
Search
Drug Profile

Iclaprim - Motif Bio

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 28 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio; Otto von Guericke University Magdeburg
  • Class Amines; Anti-infectives; Antibacterials; Antiprotozoals; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Skin and soft tissue infections
  • Phase II Nosocomial pneumonia; Ventilator associated pneumonia
  • No development reported Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Staphylococcal infections; Toxoplasmosis
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 28 Aug 2023 No recent reports of development identified for preclinical development in Staphylococcal-infections(In children) in United Kingdom
  • 28 Jun 2023 No recent reports of development identified for preclinical development in Toxoplasmosis in United Kingdom
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in United Kingdom (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top